Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped pre-market.
3 Bullish Biotech Stocks With Explosive Growth Trends These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.
